Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Applications of Tumor Immunotherapy
share announcement

Clinical Applications of Tumor Immunotherapy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 16 September 2024 | Viewed by 3908

Special Issue Editors

Dr. Giuseppe Lamberti

E-Mail Website
Guest Editor
Department of Specialized, Experimental and Diagnostic Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Interests: neuroendocrine tumors; small-cell lung cancer; immunotherapy; clinical research; precision oncology
Special Issues, Collections and Topics in MDPI journals
Dr. Elisa Andrini

E-Mail Website
Guest Editor
Department of Specialized, Experimental and Diagnostic Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Interests: neuroendocrine tumors; small-cell lung cancer; immunotherapy; clinical research; precision oncology

Special Issue Information

Dear Colleagues,

The advent of tumor immunotherapy had a significant impact on the treatment landscape of several hematological and solid tumors. The use of immune checkpoint inhibitors (ICIs) is by far the strategy with the most dramatic impact and widest adoption in tumor immunotherapy. These agents block inhibitory interactions between cancer and immune cells, thus prompting antitumor immunity and averting tumor evasion of the immune response. Adoptive cell therapies, such as chimeric antigen receptor T (CAR-T) cells, have been proven to be effective in some hematologic malignancies, with uncertain results in solid tumors. Several other tumor immunotherapy approaches, e.g., therapeutic vaccines and bispecific T cell engagers (BiTE), among others, are actively investigated, with promising results.

Irrespective of the type considered, tumor immunotherapies yielded unprecedented benefits in hard-to-treat tumors in terms of long-lasting responses and the prolongation of survival outcomes, with a peculiar toxicity profile that can be insidious. Research on tumor immunotherapy is brisk and active, currently focusing on how to increase the proportion of patients that benefit from different immunotherapy approaches and on identifying predictive biomarkers of response; thus, it is critical to understand how available evidence and findings, as well as future perspectives, translate into resources for clinical practice.

Dr. Giuseppe Lamberti
Dr. Elisa Andrini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • PD-1/PD-L1
  • CTLA-4
  • novel biomarkers
  • personalized oncology
  • tumor vaccine
  • cell therapy
  • adoptive immunotherapy
  • T cell engagers

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1130 KiB  
Article
Microbiota-Derived Short-Chain Fatty Acids Boost Antitumoral Natural Killer Cell Activity
by Marina Pérez, Berta Buey, Pilar Corral, David Giraldos and Eva Latorre
J. Clin. Med. 2024, 13(13), 3885; https://doi.org/10.3390/jcm13133885 - 2 Jul 2024
Viewed by 688
Abstract
Background: The intestinal microbiota can regulate numerous host functions, including the immune response. Through fermentation, the microbiota produces and releases microbial metabolites such as short-chain fatty acids (SCFAs), which can affect host homeostasis. There is growing evidence that the gut microbiome can have [...] Read more.
Background: The intestinal microbiota can regulate numerous host functions, including the immune response. Through fermentation, the microbiota produces and releases microbial metabolites such as short-chain fatty acids (SCFAs), which can affect host homeostasis. There is growing evidence that the gut microbiome can have a major impact on cancer. Specific gut microbial composition and metabolites are associated with tumor status in the host. However, their effects on the antitumor response have scarcely been investigated. Natural killer (NK) cells play an important role in antitumor immunity due to their ability to directly identify and eliminate tumor cells. Methods: The aim of this study was to investigate the effects of SCFAs on antitumoral NK cell activity, using NK-92 cell line. Results: Here, we describe how SCFAs can boost antitumoral NK cell activity. The SCFAs induced the release of NK extracellular vesicles and reduced the secretion of the anti-inflammatory cytokine IL-10. The SCFAs also increased the cytotoxicity of the NK cells against multiple myeloma cells. Conclusions: Our results indicate, for the first time, the enormous potential of SCFAs in regulating antitumoral NK cell defense, where modulation of the SCFAs’ production could play a fundamental role in cancer immunotherapy. Full article
(This article belongs to the Special Issue Clinical Applications of Tumor Immunotherapy)
►▼ Show Figures

Figure 1

14 pages, 816 KiB  
Article
A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
by Jong-Min Baek, Hyungkeun Cha, Yeonsook Moon, Lucia Kim, Seung Min Kwak, Eun Sun Park and Hae-Seong Nam
J. Clin. Med. 2024, 13(5), 1521; https://doi.org/10.3390/jcm13051521 - 6 Mar 2024
Viewed by 1067
Abstract
Background: No studies have identified combined biomarkers that may be more reasonable for the assessment of current chemo-immunotherapy in patients with extensive stage small-cell lung cancer (ES-SCLC). Methods: This study was conducted to investigate a combined biomarker with prognostic or predictive [...] Read more.
Background: No studies have identified combined biomarkers that may be more reasonable for the assessment of current chemo-immunotherapy in patients with extensive stage small-cell lung cancer (ES-SCLC). Methods: This study was conducted to investigate a combined biomarker with prognostic or predictive value in ES-SCLC. We determined the best independent prognostic biomarker among the four complete blood-count-derived inflammatory biomarkers (CBC-IBs). Subsequently, we analyzed the prognostic or predictive value of combining this independent CBC-IB with PD-L1 (SP142) expression. We prospectively assessed the SP142 analyses in tumor samples at diagnosis. Results: All in all, 55 patients with ES-SCLC were classified into four groups according to the systemic immune inflammation index (SII) (low/high) and SP142 (positive/negative). The best survival was observed in the low-SII/ SP142-positive group, whereas the worst survival was observed in the high-SII/SP142-negative group (p = 0.002). The combined SII-SP142 biomarker was better for predicting both survival and disease progression in patients with ES-SCLC. Conclusions: The combined SII-SP142 biomarker can be readily and universally obtained at a low cost in clinical practice, without requiring advanced genomics technology or specialized expertise. Although further studies are needed to confirm that the combined SII-SP142 biomarker is widely applicable, it should help clinicians to identify the best patients for combined chemotherapy with atezolizumab in ES-SCLC. Full article
(This article belongs to the Special Issue Clinical Applications of Tumor Immunotherapy)
►▼ Show Figures

Figure 1

15 pages, 3271 KiB  
Article
DR5 Up-Regulation Induced by Dichloroacetate Sensitizes Tumor Cells to Lipid Nanoparticles Decorated with TRAIL
by Joaquín Marco-Brualla, Diego de Miguel, Luis Martínez-Lostao and Alberto Anel
J. Clin. Med. 2023, 12(2), 608; https://doi.org/10.3390/jcm12020608 - 12 Jan 2023
Cited by 3 | Viewed by 1917
Abstract
Cancer resistance to treatments is a challenge that researchers constantly seek to overcome. For instance, TNF-related apoptosis-inducing ligand (TRAIL) is a potential good prospect as an anti-cancer therapy, as it attacks tumor cells but not normal cells. However, treatments based in soluble TRAIL [...] Read more.
Cancer resistance to treatments is a challenge that researchers constantly seek to overcome. For instance, TNF-related apoptosis-inducing ligand (TRAIL) is a potential good prospect as an anti-cancer therapy, as it attacks tumor cells but not normal cells. However, treatments based in soluble TRAIL provided incomplete clinical results and diverse formulations have been developed to improve its bioactivity. In previous works, we generated a new TRAIL formulation based in its attachment to the surface of unilamellar nanoliposomes (LUV-TRAIL). This formulation greatly increased apoptosis in a wide selection of tumor cell types, albeit a few of them remained resistant. On the other hand, it has been described that a metabolic shift in cancer cells can also alter its sensitivity to other treatments. In this work, we sought to increase the sensitivity of several tumor cell types resistant to LUV-TRAIL by previous exposure to the metabolic drug dichloroacetate (DCA), which forces oxidative phosphorylation. Results showed that DCA + LUV-TRAIL had a synergistic effect on both lung adenocarcinoma A549, colorectal HT29, and breast cancer MCF7 cells. Despite DCA inducing intracellular changes in a cell-type specific way, the increase in cell death by apoptosis was clearly correlated with an increase in death receptor 5 (DR5) surface expression in all cell lines. Therefore, DCA-induced metabolic shift emerges as a suitable option to overcome TRAIL resistance in cancer cells. Full article
(This article belongs to the Special Issue Clinical Applications of Tumor Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop